Efficacy and Immunogenicity of rKVAC85B in a BCG Prime-Boost Regimen Against H37Rv and HN878 Tuberculosis Strains
Mycobacterium tuberculosis was responsible for 1.3 million deaths worldwide in 2022. Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB); however, it has limited protective efficacy in adults. In this study, we constructed a recombinant vaccinia virus expressing Ag85B from M. tuberculosis using a novel attenuated vaccinia virus (KVAC103). We then analyzed the immunogenicity of prime-boost inoculation strategies using recombinant KVAC103 expressing Ag85B (rKVAC85B) compared to BCG. In both the rKVAC85B prime-boost and the BCG prime-rKVAC85B boost inoculation regimens, rKVAC85B induced the generation of specific IgG and the secretion of IFN-γ by immune cells. In vitro analysis of Mycobacterium growth inhibition revealed a comparable immune-mediated pattern of outcomes. Furthermore, bacterial loads in the lungs were significantly lower in mice inoculated with the BCG prime-rKVAC85B boost, than in the BCG-only group following a rechallenge infection with both H37Rv and HN878 strains of M. tuberculosis. These findings collectively suggest that KVAC103, incorporated into a viral vector, is a promising candidate for a novel TB vaccine platform that is effective against multiple TB strains, including H37Rv and HN878, and that rKVAC85B effectively stimulates immune responses against TB infection..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Preprints.org - (2024) vom: 11. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shin, Eunkyung [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.20944/preprints202403.0351.v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
preprintsorg042867789 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | preprintsorg042867789 | ||
| 003 | DE-627 | ||
| 005 | 20240312120331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20944/preprints202403.0351.v1 |2 doi | |
| 024 | 7 | |a 10.20944/preprints202403.0351.v1 |2 doi | |
| 035 | |a (DE-627)preprintsorg042867789 | ||
| 035 | |a (preprintsorg)10.20944/preprints202403.0351 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shin, Eunkyung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Immunogenicity of rKVAC85B in a BCG Prime-Boost Regimen Against H37Rv and HN878 Tuberculosis Strains |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Mycobacterium tuberculosis was responsible for 1.3 million deaths worldwide in 2022. Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB); however, it has limited protective efficacy in adults. In this study, we constructed a recombinant vaccinia virus expressing Ag85B from M. tuberculosis using a novel attenuated vaccinia virus (KVAC103). We then analyzed the immunogenicity of prime-boost inoculation strategies using recombinant KVAC103 expressing Ag85B (rKVAC85B) compared to BCG. In both the rKVAC85B prime-boost and the BCG prime-rKVAC85B boost inoculation regimens, rKVAC85B induced the generation of specific IgG and the secretion of IFN-γ by immune cells. In vitro analysis of Mycobacterium growth inhibition revealed a comparable immune-mediated pattern of outcomes. Furthermore, bacterial loads in the lungs were significantly lower in mice inoculated with the BCG prime-rKVAC85B boost, than in the BCG-only group following a rechallenge infection with both H37Rv and HN878 strains of M. tuberculosis. These findings collectively suggest that KVAC103, incorporated into a viral vector, is a promising candidate for a novel TB vaccine platform that is effective against multiple TB strains, including H37Rv and HN878, and that rKVAC85B effectively stimulates immune responses against TB infection. | ||
| 700 | 1 | |a Yun, Jin-Seung |4 aut | |
| 700 | 1 | |a Lee, Young-Ran |4 aut | |
| 700 | 1 | |a Cha, Hye-Ran |4 aut | |
| 700 | 1 | |a Kim, Soo-Min |4 aut | |
| 700 | 1 | |a Shin, Sung-Jae |0 (orcid)0000-0003-0854-4582 |4 aut | |
| 700 | 1 | |a Lee, Sang-Won |4 aut | |
| 700 | 1 | |a Chung, Gyung Tae |4 aut | |
| 700 | 1 | |a Kim, Dokeun |4 aut | |
| 700 | 1 | |a Yoo, Jung Sik |4 aut | |
| 700 | 1 | |a Kim, Jong-Seok |4 aut | |
| 700 | 1 | |a Jeong, Hye-Sook |0 (orcid)0000-0002-0998-5569 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2024) vom: 11. März |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202403.0351.v1 |z kostenfrei |3 Volltext |
| 912 | |a preprintsorg | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 03 | ||